Supplementary Data Sample Clauses

Supplementary Data. The Seller will provide the Buyer with data supplementary to the Provisioning Data, comprising local manufacture tables, ground support equipment, specific-to-type tools and a pool item candidate list.
AutoNDA by SimpleDocs
Supplementary Data. The Seller will provide the Buyer with Local Manufacture Tables (X-File), as part of the Illustrated Parts Catalog (Additional Cross-Reference Tables), which will be a part of the Initial Provisioning Data Package.
Supplementary Data. The Seller shall provide the Buyer with supplementary data to the Initial Provisioning Data, including Local Manufacture Tables (X-File) and Ground Support Equipment and Specific (To-Type) Tools (W-File) in accordance with SPEC 2000, Chapter 1.
Supplementary Data. AirPlus may provide supplementary information about transactions if Customer requested the provision of such on the Account application. AirPlus cannot provide such supplementary data without the cooperation of Customer’s travel agent(s), and Customer will need to make arrangements with its travel agent(s) for the provision of the services necessary for AirPlus to provide the supplementary data. However, Customer shall not be entitled to withhold payment from AirPlus on the grounds that any supplementary data does not appear on Customer’s statement or appears to be incorrect.
Supplementary Data. The Seller shall provide the Buyer with data supplementary to the Provisioning Data, comprising local manufacture tables, ground support equipment, specific-to-type tools and a pool item candidate list. The list of spare parts required for the installation of all airframe LRUs will be provided by the Seller to the Buyer during the Initial Provisioning Conference
Supplementary Data. The Seller will provide the Buyer with Local Manufacture Tables (X-File), and Ground Support Equipment and Specific to-type Tools (W-File) and a Pool Item Candidate List (Y-File) as a part of the Initial Provisioning Data package.
Supplementary Data. Figure S1. Age at breast cancer development (black bars) and ovarian cancer development (grey bars) for the carriers of BRCA1*R1699Q. Figure S2. Cumulative risks (%) for breast cancer (left graph) and ovarian cancer (right graph) by age for carriers of BRCA1*R1699Q based on the main analysis (blue line), sub-analysis 1 (orange line) and sub-analysis 2 (purple line). The corresponding curves or the cumulative risk conferred by average pathogenic BRCA1 variants (red line) and for the general population (green line) are also shown. Cumulative risks are calculated using segregation analysis, major gene model assuming constant relative risk. Figure S3. Cumulative risks (%) for breast cancer (left graph) and ovarian cancer (right graph) by age for carriers of BRCA1*R1699Q based on the main analysis (blue line), sub-analysis 1 (orange line) and sub-analysis 2 (purple line). The corresponding curves or the cumulative risk conferred by average pathogenic BRCA1 variants (red line) and for the general population (green line) are also shown. Cumulative risks are calculated using segregation analysis, major gene model assuming relative risk as a continuous, piecewise linear function of age. Table S1. Number and origin of families in the previous study and current study (previous plus newly included families) . Previous study10 Current study Country # Families # Families with additional genotyping (*) # Families # Families with additional genotyping (*) The Netherlands 12 3 20 15 Denmark 10 4 22 19 France 5 3 14 7 Germany 5 1 19 10 South Africa 1 1 1 1 Sweden 14 5 20 17 United Kingdom 4 2 4 2 U.S.A. 9 7 14 11 Total 69 30 129 91 (*): additional genotyping means at least one other relative tested in addition to the index. Table S2. Descriptive characteristics of the 129 families. Unknown Carriership Non-carriers Carriers Age Total BC# OC& Total BC OC Total BC OC <30 2935 1 0 100 0 0 105 4 0 30-39 89 18 2 8 1 0 37 26 1 40-49 94 26 5 27 5 0 60 39 8 50-59 124 40 26 24 4 1 53 30 24 60-69 122 36 15 6 2 0 39 11 12 70-79 96 16 7 4 2 1 11 3 6 >=80 82 10 2 4 1 0 4 0 1 Total 3542 147 57 173 15 2 309 113 52 #BC: Breast cancer &OC: Ovarian cancer 3 Table S3. Cumulative risk (95% Confidence Interval) using segregation analysis, major gene models assuming constant relative risk. Main Analysis Cumulative risk (95% Confidence Interval) Sub-Analysis 1 Cumulative risk (95% Confidence Interval) Sub-Analysis 2 Cumulative risk (95% Confidence Interval) Age Breast cancer Ovarian cancer Breast ...
AutoNDA by SimpleDocs
Supplementary Data. Genotoxicity
Supplementary Data. Supplementary data related to this article can be found online at xxxx://xx.xxx.xxx/10.1016/j.ejon.2013.03.004. Xxxxxxxx, X., Xxxxxx, X., Xxxxxxxxxx, X., Xxxxxxxx, N., 2008. Literature review of methods to translate health-related quality of life questionnaires for use in multinational clinical trials. Value in Health 11 (3), 509e521. Xxxxxxxx, J., Xxxxxxx, X.X., 1988. Structural equation modeling in practice: a review and recommended two-step approach. Psychological Bulletin 103 (3), 411e423. Xxxxxxxxx, X., Xxxx-Xxxxxxx, X.X., Xxxxxxx, X.X., Xxxxxxxx, E., Xxxxxx, B., Xxxxxxxx- Xxxxxxxxxx, X., et al., 2002. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. Journal of Clinical Oncology 20 (19), 3947e 3955. Xxxxxx, X.X., Xxxx, S.M., Xxxxx, X., Xxxxxx, X., 2009a. Using the FACT-leukemia Subscale to Evaluate Quality of Life in Leukemia Patients Worldwide. In: Poster Presented at the 12th Annual Conference of the International Society for Pharmacoeconomics and Outcomes Research October 24e27, 2009, Paris, France. Xxxxxx, X.X., Xxxx, S.M., Xxxxxxxxx, X., Xxxxx, X., Xxxxx, D., 2009b. Using the FACTlymphoma Subscale to Evaluate Quality of Life in Non-Hodgkin’s Lymphoma Patients from across the Globe. In: Poster Presented at the 16th Annual Conference of the International Society for Quality of Life Research, October 28e31, New Orleans, USA. Xxxxxxxx, X., Xxxxx, X., Xxxxxxxxx, X.X., Xxxxxxxxx, X., Xxxxxxxx, X.X., Xxxxx-Xxxxx, X.X., et al., 2011. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. International Journal of Dermatology 50 (2), 129e146. Xxxxxx, X.X., Xxxxx, X.X., Xxxx, X.X., Xxxxxxx, K., Xxxxxxx-Xxxxxxxxxx, B., Xxxxxxx, X., et al., 1996. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 5 (3), 309e320. Xxxx, X., Xxxxxxx, X., Xxxxxxxxxx, A.R., Xxxxxxxx, X., Xxxx, D., Xxxxxxx, G.A., et al., 2005. Quality of life in lung cancer: the validity and cross-cultural applicability of the Functional Assessment of Cancer Therapy-Lung scale. Hematology/ Oncology Clinics of North America 19 (2), 389e420. viii. Xxxxx, X.X., 1994. Quality of life: concepts and definition. Journal of Pain and Symptom Management 9 (3), 186e192. Xxxxx, D., Xx...
Supplementary Data. (3.0)%====== (6.1)%====== (7.8)%====== EBITDA(1)................................................. 16.4% 10.6% 9.7% ---------------
Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!